Smaller Default Larger

Previous studies have shown that patients with non-O blood group receiving high doses of IVIG (2 g/kg) appear to be at highest risk of hemolysis. 

The purpose of this study is to:

  • understand the patient and product factors that result in moderate to severe hemolysis following infusion of IVIG
  • determine the actual incidence of IVIG-associated hemolysis
  • and to identify specific risk factors which might enable clinicians to decrease or prevent this complication